利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.029 秒)

    Resorbable interbody spinal fusion devices
    1.
    发明授权
    Resorbable interbody spinal fusion devices 失效
    可再生体内脊柱融合装置

    公开(公告)号：US07077866B2

    公开(公告)日：2006-07-18

    申请号：US09785593

    申请日：2001-02-16

    申请人： Joseph D. Gresser ,  Debra J. Trantolo ,  Robert S. Langer ,  Kai-Uwe Lewandrowski ,  Alexander M. Klibanov ,  Donald L. Wise

    发明人： Joseph D. Gresser ,  Debra J. Trantolo ,  Robert S. Langer ,  Kai-Uwe Lewandrowski ,  Alexander M. Klibanov ,  Donald L. Wise

    IPC分类号： A61F2/44

    CPC分类号： A61F2/4455 ,  A61F2/30965 ,  A61F2/442 ,  A61F2002/2835 ,  A61F2002/30062 ,  A61F2002/30112 ,  A61F2002/30133 ,  A61F2002/30153 ,  A61F2002/30179 ,  A61F2002/30217 ,  A61F2002/30772 ,  A61F2002/30785 ,  A61F2002/30789 ,  A61F2002/30868 ,  A61F2002/30904 ,  A61F2002/30957 ,  A61F2210/0004 ,  A61F2230/0004 ,  A61F2230/0015 ,  A61F2230/0019 ,  A61F2230/0058 ,  A61F2230/0067 ,  Y10S623/926

    摘要： A resorbable interbody fusion device for use in spinal fixation is disclosed. The device is composed of 25–100% bioresorbable or resorbable material. The interbody fusion device of the invention can be in any convenient form, such as a wedge, screw or cage. Preferably, the resorbable device of the invention is in the shape of a tapered wedge or cone, which further desirably incorporates structural features such as serrations or threads better to anchor the device in the adjoining vertebrae. The preferred device further comprises a plurality of peripheral voids and more desirably a central void space therein, which may desirably be filled with a grafting material for facilitating bony development and/or spinal fusion, such as an autologous grafting material. As the preferred material from which the resorbable interbody fusion device is manufactured is most likely to be a polymer that can produce acidic products upon hydrolytic degradation, the device preferably further includes a neutralization compound, or buffer, in sufficiently high concentration to decrease the rate of pH change as the device degrades, in order to prevent sterile abscess formation caused by the accumulation of unbuffered acidic products in the area of the implant.

    摘要翻译： 公开了一种用于脊柱固定的可再吸收体内融合装置。 该装置由25-100％的生物可吸收或可再吸收材料组成。 本发明的体内融合装置可以是任何方便的形式，例如楔形物，螺钉或笼子。 优选地，本发明的可再吸收装置是锥形楔形或锥形的形状，其进一步期望地包括诸如锯齿或线的结构特征，以更好地将装置锚定在相邻的椎骨中。 优选的装置还包括多个周边空隙，并且更期望地为其中的中心空隙空间，其可期望地填充有用于促进骨发育和/或脊柱融合的接枝材料，例如自体移植材料。 作为制造可再吸收的体内融合装置的优选材料最可能是在水解降解时可以产生酸性产物的聚合物，该装置优选还包含足够高浓度的中和化合物或缓冲剂，以降低 pH值随器械降解而改变，以防止在植入物区域积聚无缓冲酸性产物引起的无菌性脓肿形成。

    Abuse-Deterrent Pharmaceutical Compositions of Opiods and Other Drugs
    8.
    发明申请
    Abuse-Deterrent Pharmaceutical Compositions of Opiods and Other Drugs 有权
    鸦片和其他药物的滥用威慑药物组合物

    公开(公告)号：US20130045960A1

    公开(公告)日：2013-02-21

    申请号：US13551455

    申请日：2012-07-17

    申请人： Jane Hirsh ,  Alexander M. Klibanov ,  Timothy M. Swager ,  Stephen L. Buchwald ,  Whe Yong Lo ,  Alison Fleming ,  Roman V. Rariy

    发明人： Jane Hirsh ,  Alexander M. Klibanov ,  Timothy M. Swager ,  Stephen L. Buchwald ,  Whe Yong Lo ,  Alison Fleming ,  Roman V. Rariy

    IPC分类号： A61K31/555 ,  A61K31/485 ,  C07D489/08 ,  A61P25/36 ,  C07F3/06

    CPC分类号： A61K31/485 ,  A61K9/145 ,  A61K9/1617 ,  A61K9/1682 ,  A61K9/1694 ,  A61K9/4858 ,  A61K9/50 ,  A61K9/5052 ,  A61K9/5084 ,  A61K31/20 ,  A61K47/12

    摘要： An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.

    摘要翻译： 已经开发了一种滥用威慑药物组合物，以减少药物不当管理的可能性，特别是诸如阿片类药物。 在优选的实施方案中，修饰药物以增加其亲油性。 在优选实施方案中，改性药物均匀地分散在由缓慢溶解或不溶于水的材料组成的微粒内。 即使制剂的物理完整性受到损害（例如通过用刀片切碎或破碎）并且将所得材料置于水中，嗅到或吞咽，滥用威慑组合物也会延缓释放药物。 然而，当按照指导施用时，通过酶降解，胆汁酸的表面活性作用和机械侵蚀的组合，组合物被分解或逐渐溶解在胃肠道内，药物从组合物中缓慢释放。

    ABUSE-DETERRENT DRUG FORMULATIONS
    9.
    发明申请
    ABUSE-DETERRENT DRUG FORMULATIONS 有权
    滥用药物制剂

    公开(公告)号：US20100260834A1

    公开(公告)日：2010-10-14

    申请号：US12823628

    申请日：2010-06-25

    申请人： Jane C. Hirsh ,  Alison B. Fleming ,  Roman V. Rariy ,  Alexander M. Klibanov

    发明人： Jane C. Hirsh ,  Alison B. Fleming ,  Roman V. Rariy ,  Alexander M. Klibanov

    IPC分类号： A61K9/50 ,  A61K31/485 ,  A61K9/48 ,  A61P25/04

    CPC分类号： A61K31/485 ,  A61K9/0053 ,  A61K9/145 ,  A61K9/148 ,  A61K9/1617 ,  A61K9/1664 ,  A61K9/2013 ,  A61K9/4808 ,  A61K9/4858 ,  A61K9/5015 ,  A61K9/5042 ,  A61K31/13 ,  A61K31/20 ,  A61K45/06 ,  A61K47/12 ,  A61K2300/00

    摘要： An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble. The abuse-deterrent composition prevents the immediate release of a substantial portion of drag, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.

    摘要翻译： 已经开发了一种滥用威慑药物组合物，以减少药物不当管理的可能性，特别是诸如阿片类药物。 在优选的实施方案中，通过在药物和一种或多种脂肪酸之间形成盐，来修饰药物以增加其亲油性，其中一种或多种脂肪酸的浓度是活性剂的摩尔量的1至15倍 活性剂摩尔量的2〜10倍。 在一个实施方案中，改性药物均匀地分散在由缓慢溶解或不溶于水的材料组成的微粒内。 在一些实施方案中，含有微粒或药物颗粒的药物涂覆有一个或多个涂层，其中至少一个涂层是水不溶性的，优选有机溶剂不溶。 即使制剂的物理完整性受到损害（例如通过用刀片切碎或破碎）并且将所得材料放置在水中，嗅到或or or or or or or or or or or or or or or or or or or or or or or or or or 吞下去 然而，当按照指导给药时，由于组合物通过酶降解，胆汁酸的表面活性作用和机械侵蚀的组合被分解或逐渐溶解在胃肠道内，药物从组合物中缓慢释放。

    Enzymatic temperature change indicator
    10.
    发明授权
    Enzymatic temperature change indicator 失效
    酶温变化指​​标

    公开(公告)号：US4826762A

    公开(公告)日：1989-05-02

    申请号：US112893

    申请日：1987-10-23

    申请人： Alexander M. Klibanov ,  Jonathan S. Dordick

    发明人： Alexander M. Klibanov ,  Jonathan S. Dordick

    IPC分类号： C12Q1/28 ,  G01K11/06 ,  G01N31/22

    CPC分类号： G01N31/229 ,  C12Q1/28 ,  G01K11/06 ,  Y10S435/81

    摘要： A temperature change indicator is described which is composed of an enzyme and a substrate for that enzyme suspended in a solid organic solvent or mixture of solvents as a support medium. The organic solvent or solvents are chosen so as to melt at a specific temperature or in a specific temperature range. When the temperature of the indicator is elevated above the chosen, or critical temperature, the solid organic solvent support will melt, and the enzymatic reaction will occur, producing a visually detectable product which is stable to further temperature variation.

    摘要翻译： 描述了温度变化指示器，其由酶和用于该酶悬浮在固体有机溶剂或作为载体介质的溶剂混合物中的底物组成。 选择有机溶剂或溶剂以在特定温度或特定温度范围内熔融。 当指示剂的温度升高到所选择或临界温度以上时，固体有机溶剂载体将熔化，并发生酶反应，产生视觉上可检测的产物，其对于进一步的温度变化是稳定的。